🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-521526-15-00
Authorised Phase IV

PHASE IV, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY ON THE PAIN-RELIEF EFFECT OF BENZYDAMINE HYDROCHLORIDE LOZENGES 3 MG MINT TASTE (TANTUM VERDE) IN NON STREPTOCOCCAL PHARYNGOTONSILLITIS IN PEDIATRIC AGE (6-11 YEARS OLD).

2025-521526-15-00 · tracked via the Priya Life Science EU tracker
Sponsor
Angelini Pharma Italia Aziende Chimiche Riunite Angelini Francesc O A.C.R.A.F. S.p.A. Enunciabile Anche Angelini Pharma Italia S.p.A. Angelini Pharma S.p.A. A.C.R.A.F. S.p.A. Acraf S.p.A. Angelini S.p.A. Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.
Sponsor type
Pharmaceutical company
Therapeutic area
Respiratory Tract Diseases
Decision date
30/04/2026
Enrollment target
120
Sites
Italy

Condition studied

NON STREPTOCOCCAL PHARYNGOTONSILLITIS

Investigational medicinal product(s)

Tantum Verde P 3 mg pastiglie gusto menta

Eligibility

Age group
0-17 years
Sex
Female, Male

Primary endpoint

Repeated-measures association during the first 60 minutes after first lozenge placement between change from baseline in the percentage of pharyngotonsillar surface area above the pre-specified temperature threshold, assessed centrally on duplicate infrared images., Repeated-measures association during the first 60 minutes after first lozenge placement between change from baseline in WBFPRS assessed at 5, 10, 15, 20, 25, 30 and 60 minutes.

Endpoint detail

Time from first lozenge placement to first clinically meaningful pain reduction (≥2-point decrease in WBFPRS)., Time from first lozenge placement to first predefined thermographic improvement (defined as a relative reduction from baseline of at least 15% in the percentage of pharyngotonsillar surface area above the prespecified temperature threshold)., Proportion of participants with clinically meaningful pain reduction at 5, 10, 15, 20, 25, 30, 60 minutes and at 24, 48 and 72 hours., Mean and median change from baseline in WBFPRS at each scheduled time-point., Time to complete pain disappearance (WBFPRS = 0)., Number of lozenges taken before complete pain disappearance., Descriptive association between change from baseline in the percentage of pharyngotonsillar surface area above the pre-specified temperature threshold and change from baseline in WBFPRS over 24, 48 and 72 hours., Supportive analyses referenced to the time of complete lozenge dissolution., Need for paracetamol and/or antibiotics during the study., Safety outcomes including adverse events, vital signs, oral temperature, and physical examination findings., Number and percentage of patients who discontinued the investigational medicinal product, with the reason for discontinuation.

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-521526-15-00 on CTIS ↗ ← All trials in the EU